Evaluation of silodosin versus tadalafil in patients with urination disorders associated with benign prostatic hyperplasia
Not Applicable
- Conditions
- Benign Prostatic Hyperplasia
- Registration Number
- JPRN-UMIN000018743
- Lead Sponsor
- Kissei Pharmaceutical Co.,Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 180
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients have any of the contraindications listed in the package inserts for silodosin or tadalafil. 2) Patients have prostate cancer. 3) Patients have lower urinary tract symptoms possibly due to urinary tract infection or neurogenic bladder. 4) Patients have used silodosin or tadalafil within 12 weeks prior to Week 0.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in total IPSS score before and after treatment
- Secondary Outcome Measures
Name Time Method